ACN
29
-2
NEE
59
5
LUV
48
-2
EXPE
56
-3
JNJ
32
6
IFF
44
-3
AON
19
2
UPS
46
-2
CA
12
-8
TDC
70
3
COF
63
-2
GWW
43
-12
LYB
37
-2
LNC
45
2
OXY
45
-4
EMC
54
-4
INTU
65
-2
URBN
52
-3
DG
26
-2
GIS
58
-3
ACN
29
-2
NEE
59
5
LUV
48
-2
EXPE
56
-3
JNJ
32
6
IFF
44
-3
AON
19
2
UPS
46
-2
CA
12
-8
TDC
70
3
COF
63
-2
GWW
43
-12
LYB
37
-2
LNC
45
2
OXY
45
-4
EMC
54
-4
INTU
65
-2
URBN
52
-3
DG
26
-2
GIS
58
-3
Financhill
Back

Eli Lilly and 10K Form

Buy
68

LLY
Eli Lilly and

Last Price:
777.16
Seasonality Move:
3.51%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive LLY News And Ratings

See the #1 stock for the next 7 days that we like better than LLY

LLY Financial Statistics

Sales & Book Value

Annual Sales: $34.12B
Cash Flow: $83.2M
Price / Cash Flow: 0
Annual Sales: $13.48
Price / Book: 57.62

Profitability

EPS (TTM): 6.67640
Net Income (TTM): $6.14B
Gross Margin: $27.04B
Return on Equity: 53.37%
Return on Assets: 10.45%

Eli Lilly and Earnings Forecast

Key Eli Lilly and Financial Ratios

  • The Gross Profit Margin over the past 40 years for LLY is 79.25%.
  • The Selling, General & Administrative Expenses for LLY have been equal to 20.34% of Gross Profit Margin.
  • The Research & Development expenses have been 27.29% of Revenue.
  • The Interest Expense is 9.27% of Operating Income.
  • The Net Earning history of LLY is 15.36% of Total Revenues.
  • Per Share Earnings over the last 40 years have been positive in 23 years.

Eli Lilly and Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: S&P500
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: LLY
CUSIP: 532457
Website: lilly.com

Debt

Debt-to-Equity Ratio: 2.05
Current Ratio: 1.35
Quick Ratio: 0.68

Price-to-Earnings

Trailing P/E Ratio: 133.92
Forward P/E Ratio: 41.61

LLY Technical Analysis vs Fundamental Analysis

Buy
68
Eli Lilly and (LLY) is a Buy

Is Eli Lilly and a Buy or a Sell?

  • Eli Lilly and stock is rated a Buy
    The current Eli Lilly and [LLY] share price is $776.75. The Score for LLY is 68, which is 36% above its historic median score of 50, and infers lower risk than normal.